Compare Fox Corp Class B (FOX) vs GSK plc (GSK) Price & Performance

FOX trades at $49.50, down 1.43% today, with technical indicators showing a neutral to bearish short-term bias. The company demonstrates strong fundamental performance with Q1 2026 EPS beating expectations at $1.32 versus $0.988, continuing a trend of earnings surprises. Revenue grew to $16.3B in 2025 with net income margin expanding to 13.88%. Analyst sentiment is mixed with 43% buy ratings but technical weakness persists near key support levels.

The outlook remains cautiously optimistic given FOX's consistent earnings beats and improved cash flow generation, though technical weakness and competitive pressures in media streaming present near-term challenges. The stock offers reasonable valuation with P/E of 13.26x, but investors should monitor advertising trends and Roku integration execution risks.

GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.

The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.